Free tool
FAERS Monitor: Vivitrol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021897 or its brand name (Vivitrol, Naltrexone). Reports on generic versions are filed under their own applications.
Reports
31,043
Serious
8,878
29% of reports
Hospitalization
3,948
Death reported
1,344
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site reaction4,410
- injection site pain3,180
- nausea2,165
- alcoholism1,959
- injection site mass1,927
- fatigue1,824
- pain1,671
- drug ineffective1,580
- off label use1,525
- headache1,516
- feeling abnormal1,412
- drug dependence1,378
- malaise1,274
- insomnia1,160
- anxiety1,106
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 36 |
| 2006 | 23 |
| 2007 | 52 |
| 2008 | 62 |
| 2009 | 38 |
| 2010 | 51 |
| 2011 | 55 |
| 2012 | 123 |
| 2013 | 151 |
| 2014 | 281 |
| 2015 | 1,180 |
| 2016 | 1,861 |
| 2017 | 2,273 |
| 2018 | 6,405 |
| 2019 | 3,346 |
| 2020 | 3,695 |
| 2021 | 2,783 |
| 2022 | 2,581 |
| 2023 | 1,962 |
| 2024 | 1,465 |
| 2025 | 1,428 |
| 2026 | 1,185 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,023,116 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| alcoholismSignal | 1,959 | 570.4 | 537.7 | 604,217 |
| injection site reactionSignal | 4,410 | 46.3 | 45.0 | 183,602 |
| injection site massSignal | 1,927 | 37.2 | 35.6 | 64,410 |
| injection site painSignal | 3,180 | 7.1 | 6.9 | 16,691 |
| drug dependenceSignal | 1,378 | 5.8 | 5.6 | 5,528 |
| feeling abnormalSignal | 1,412 | 4.0 | 3.8 | 3,205 |
| insomniaSignal | 1,160 | 3.0 | 2.8 | 1,516 |
| anxietySignal | 1,106 | 2.6 | 2.5 | 1,136 |
| malaise | 1,274 | 2.0 | 1.9 | 620 |
| nausea | 2,165 | 1.9 | 1.8 | 884 |
| pain | 1,671 | 1.8 | 1.8 | 664 |
| headache | 1,516 | 1.6 | 1.6 | 389 |
| fatigue | 1,824 | 1.6 | 1.5 | 412 |
| off label use | 1,525 | 1.2 | 1.1 | 44 |
| drug ineffective | 1,580 | 0.8 | 0.8 | 73 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.